Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 353-360

  Birault, Véronique ^a   Solari, Roberto ^b   Hanrahan, John ^c   Thomas, David Y ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYCLOHEXYLOXY 2 (1 (4 (4 METHOXYBENZENESULFONYL)PIPERAZIN 1 YL)ETHYL)QUINAZOLINE; AGENTS AFFECTING PROTEIN METABOLISM; CARDIAC GLYCOSIDE; CYCLOPROPANECARBOXAMIDE 1 (2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL) N [1 [(2R) 2,3 DIHYDROXYPROPYL] 6 FLUORO 2 (2 HYDROXY 1,1 DIMETHYLETHYL) 1H INDOL 5 YL]; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; F508DEL CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLAFENINE; HISTONE DEACETYLASE INHIBITOR; IBUPROFEN; IVACAFTOR; LATONDUINE; LUMACAFTOR; MIGLUSTAT; N [2 [(5 CHLORO 2 METHOXYPHENYL)AMINO] 4' METHYL 4,5' BI 1,3 THIAZOL 2' YL]BENZAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OUABAIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; SILDENAFIL; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; VELIPARIB; VORINOSTAT; VRT 325; VX 661;

CELL FUNCTION; CELL MEMBRANE; CYSTIC FIBROSIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOPLASMIC RETICULUM; HUMAN; LUNG FIBROSIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PROTEIN TRANSPORT; QUALITY CONTROL; REVIEW;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG ADMINISTRATION ROUTES; DRUG DISCOVERY; HUMANS; MUTATION; PROTEIN TRANSPORT;

EID: 84878827634     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.020     Document Type: Review

References (42)

1. Dalemans W., Barbry P., Champigny G., Jallat S., Dott K., Dreyer D., Crystal R.G., Pavirani A., Lecocq J.P., Lazdunski M. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991, 354:526-528.
2. Lukacs G.L., Chang X.B., Bear C., Kartner N., Mohamed A., Riordan J.R., Grinstein S. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 1993, 268:21592-21598.
3. Molinski S., Eckford P.D., Pasyk S., Ahmadi S., Chin S., Bear C.E. Functional rescue of F508del-CFTR using small molecule correctors. Front Pharmacol 2012, 3. (article 160).
4. Amaral M.D., Farinha C.M. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 2013, (Epub ahead of print).
5. Pedemonte N., Galietta L.J. Pharmacological correctors of mutant CFTR mistrafficking. Front Pharmacol 2012, 3. (article 175).
6. Hanrahan J.W., Sampson H.M., Thomas D.Y. Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 2013, 34:119-125.
7. Lukacs G.L., Verkman A.S. CFTR folding, misfolding and correcting the deltaF508 conformational defect. Trends Mol Med 2012, 18:81-91.
8. - transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005, 289:L1123-L1130.
9. Zhang L., Button B., Gabriel S.E., Burkett S., Yan Y., Skiadopoulos M.H., Dang Y.L., Vogel L.N., McKay T., Mengos A., Boucher R.C., et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009, 7:e1000155.
10. Maattanen P., Gehring K., Bergeron J.J., Thomas D.Y. Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol 2010, 21:500-511.
11. Wang B., Heath-Engel H., Zhang D., Nguyen N., Thomas D.Y., Hanrahan J.W., Shore G.C. Bap31 interacts with SEC61 translocons and promotes retrotranslocation of CFTRdeltaF508 via the Derlin-1 complex. Cell 2008, 133:1080-1092.
12. Wang X., Venable J., LaPointe P., Hutt D.M., Koulov A.V., Coppinger J., Gurkan C., Kellner W., Matteson J., Plutner H., Riordan J.R., et al. Hsp90 cochaperone aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127:803-815.
13. Jansen G., Lee A.Y., Epp E., Fredette A., Surprenant J., Harcus D., Scott M., Tan E., Nishimura T., Whiteway M., Hallett M., et al. Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol 2009, 5. (article 338).
14. Zhang D., Ciciriello F., Anjos S.M., Carissimo A., Liao J., Carlile G.W., Balghi H., Robert R., Luini A., Hanrahan J.W., Thomas D.Y. Ouabain mimics low temperature rescue of F508del-cCFTR in cystic fibrosis epithelial cells. Front Pharmacol 2012, 3. (article 176).
15. Bisignano P., Moran O. Molecular dynamics analysis of the wild type and delF508 mutant structures of the human CFTR-nucleotide binding domain 1. Biochimie 2010, 92:51-57.
16. Hunt J.F., Wang C., Ford R.C. Cystic fibrosis transmembrane conductance regulator (ABCC7) structure. Cold Spring Harb Perspect Med 2013, 3. a009514. 10.1101/cshperspect.a009514.
17. Mendoza J.L., Thomas P.J. Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J Bioenerg Biomembr 2007, 39:499-505.
18. Mendoza J.L., Schmidt A., Li Q., Nuvaga E., Barrett T., Bridges R.J., Feranchak A.P., Brautigam C.A., Thomas P.J. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 2012, 148:164-174.
19. Rabeh W.M., Bossard F., Xu H., Okiyoneda T., Bagdany M., Mulvihill C.M., Du K., di Bernardo S., Liu Y., Konermann L., Roldan A., et al. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 2012, 148:150-163.
20. Bouchecareilh M., Balch W.E. Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr Mol Med 2012, 12:815-826.
21. Loo T.W., Bartlett M.C., Clarke D.M. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 2008, 413:29-36.
22. Sampson H.M., Lam H., Chen P.C., Zhang D., Mottillo C., Mirza M., Qasim K., Shrier A., Shyng S.L., Hanrahan J.W., Thomas D.Y. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines. Orphanet J Rare Dis 2013, 8. 10.1186/1750-1172-8-11.
23. Chambers J.E., Petrova K., Tomba G., Vendruscolo M., Ron D. ADP ribosylation adapts an ER chaperone response to short-term fluctuations in unfolded protein load. J Cell Biol 2012, 198:371-385.
24. Jakab R.L., Collaco A.M., Ameen N.A. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci 2012, 57:2826-2845.
25. Trzcinska-Daneluti A.M., Nguyen L., Jiang C., Fladd C., Uehling D., Prakesch M., Al-awar R., Rotin D. Use of kinase inhibitors to correct deltaF508-CFTR function. Mol Cell Proteomics 2012, 11:745-757.
26. Venier R.E., Igdoura S.A. Miglustat as a therapeutic agent: prospects and caveats. J Med Genet 2012, 49:591-597.
27. Noel S., Wilke M., Bot A.G., De Jonge H.R., Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008, 325:1016-1023.
28. Hutt D.M., Herman D., Rodrigues A.P., Noel S., Pilewski J.M., Matteson J., Hoch B., Kellner W., Kelly J.W., Schmidt A., Thomas P.J., et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2009, 6:25-33.
29. Scroggins B.T., Robzyk K., Wang D., Marcu M.G., Tsutsumi S., Beebe K., Cotter R.J., Felts S., Toft D., Karnitz L., Rosen N., et al. An acetylation site in the middle domain of HSP90 regulates chaperone function. Mol Cell 2007, 25:151-159.
30. Carlile G.W., Robert R., Zhang D., Teske K.A., Luo Y., Hanrahan J.W., Thomas D.Y. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBioChem 2007, 8:1012-1020.
31. Robert R., Carlile G.W., Pavel C., Liu N., Anjos S.M., Liao J., Luo Y., Zhang D., Thomas D.Y., Hanrahan J.W. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008, 73:478-489.
32. Anjos S.M., Robert R., Waller D., Zhang D.L., Balghi H., Sampson H.M., Ciciriello F., Lesimple P., Carlile G.W., Goepp J., Liao J., et al. Decreasing poly(ADP-ribose) polymerase activity restores deltaF508 CFTR trafficking. Front Pharmacol 2012, 3. (article 165).
33. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010, 10:293-301.
34. Carlile G.W., Keyzers R.A., Teske K.A., Robert R., Williams D.E., Linington R.G., Gray C.A., Centko R.M., Yan L., Anjos S.M., Sampson H.M., et al. Correction of F508del-CFTR trafficking by the sponge alkaloid latonduine is modulated by interaction with PARP. Chem Biol 2012, 19:1288-1299.
35. Chambers J.E., Petrova K., Tomba G., Vendruscolo M., Ron D. AADP ribosylation adapts an ER chaperone response to short-term fluctuations in unfolded protein load. J Cell Biol 2012, 198:371-385.
36. Jwa M., Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1alpha-mediated unfolded protein response. Nat Cell Biol 2012, 14:1223-1230.
37. Robert R., Carlile G.W., Liao J., Balghi H., Lesimple P., Liu N., Kus B., Rotin D., Wilke M., de Jonge H.R., Scholte B.J., et al. Correction of the delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010, 77:922-930.
38. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
39. Micel L.N., Tentler J.J., Smith P.G., Eckhardt S.G. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 2013, (Epub 2013 Jan 28).
40. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., Ballmann M., Boyle M.P., Bronsveld I., Campbell P.W., De Boeck K., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67:12-18.
41. Lin S., Sui J., Cotard S., Fung B., Andersen J., Zhu P., El Messadi N., Lehar J., Lee M., Staunton J. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Assay Drug Dev Technol 2010, 8:669-684.
42. Noel S., Dhooghe B., Leal T. PDE5 inhibitors as potential tools in the treatment of cystic fibrosis. Front Pharmacol 2012, 3. (article 167).